Agreement - August 11, 2025
Sever Pharma Solutions expands partnership with Silo Pharma
Under the new agreement, Sever Pharma Solutions will scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia.
Agreement - August 11, 2025
Nanexa signs agreement with major pharma company
The company has announced the signing of an extension of a feasibility agreement with a major pharmaceutical company to investigate the use of Nanexa's PharmaShell platform for a specific drug with current yearly sales exceeding USD 1 billion.
Denmark - August 6, 2025
Novo Nordisk lowers sales and operating profit outlook for 2025 and makes organizational changes
Novo Nordisk has announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER.
Pharma Business - August 4, 2025
Purpose Pharma receives European Commission approval of ATTROGY
The European Commission has granted ATTROGY (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Collaboration - July 29, 2025
Neuraxpharm and Dizlin Pharmaceuticals enter co-development agreement
Neuraxpharm Group and Swedish Dizlin Pharmaceuticals have announced a strategic global co-development agreement for Infudopa SubC.
Global report - July 28, 2025
AstraZeneca plans to invest USD 50 billion in US manufacturing and R&D
This investment is expected to create tens of thousands of new jobs across the country states the company.
